Investigational New Drugs

, Volume 28, Issue 1, pp 91–97

A phase II trial of Triapine® (NSC# 663249) and gemcitabine as second line treatment of advanced non-small cell lung cancer: Eastern Cooperative Oncology Group Study 1503

  • Anne M. Traynor
  • Ju-Whei Lee
  • Gerald K. Bayer
  • John M. Tate
  • Sachdev P. Thomas
  • Miroslaw Mazurczak
  • David L. Graham
  • Jill M. Kolesar
  • Joan H. Schiller
PHASE II STUDIES

Summary

Background: The objective of ECOG 1503 was to determine the response rate of this combination in the second-line treatment of advanced NSCLC. Methods: Triapine 105 mg/m2 IV on days 1, 8, and 15, and gemcitabine 1,000 mg/m2 on days 1, 8, and 15, of a 28 day cycle. Results: Eighteen patients enrolled. Three patients were not eligible due to protocol violations. No objective antitumor responses were seen. Three patients (20%) experienced stable disease (90% CI 5.7–44%). Median overall survival: 5.4 months (95% CI 4.2–11.6 months); median time to progression: 1.8 months (95% CI 1.7–3.5 months). Five patients developed acute infusion reactions to Triapine® related to elevated methemoglobinemia. Patients with MDR1 variant genotypes of C3435T experienced superior overall survival compared to non-variants (13.3 vs. 4.3 months, respectively, p = 0.023). Conclusion: This regimen did not demonstrate activity in relapsed NSCLC. Prolonged survival seen with MDR1 variant genotypes is hypothesis-generating.

Keywords

Non-small cell lung cancer Combination chemotherapy Ribonucleotide reductase Single nucleotide polymorphism ATP binding cassette transporter 

References

  1. 1.
    Schiller JH, Harrington D, Belani CP et al (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:92–98 doi:10.1056/NEJMoa011954 CrossRefPubMedGoogle Scholar
  2. 2.
    Crino L, Mosconi AM, Scagliotti G et al (1999) Gemcitabine as second-line treatment for advanced non-small-cell lung cancer: a phase II trial. J Clin Oncol 17:2081–2085PubMedGoogle Scholar
  3. 3.
    Brodowicz T, Krzakowski M, Zwitter M et al (2006) Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial. Lung Cancer 52:155–163 doi:10.1016/j.lungcan.2006.01.006 CrossRefPubMedGoogle Scholar
  4. 4.
    Murren J, Modiano M, Clairmont C et al (2003) Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors. Clin Cancer Res 9:4092–4100PubMedGoogle Scholar
  5. 5.
    Yu Y, Wong J, Lovejoy DB et al (2006) Chelators at the cancer coalface: desferrioxamine to Triapine and beyond. Clin Cancer Res 12:6876–6883 doi:10.1158/1078-0432.CCR-06-1954 CrossRefPubMedGoogle Scholar
  6. 6.
    Finch RA, Liu M, Grill SP et al (2000) Triapine (3-aminopyridine-2-carboxaldehyde- thiosemicarbazone): a potent inhibitor of ribonucleotide reductase activity with broad spectrum antitumor activity. Biochem Pharmacol 59:983–991 doi:10.1016/S0006-2952(99)00419-0 CrossRefPubMedGoogle Scholar
  7. 7.
    Sigmond J, Kamphuis JA, Laan AC et al (2007) The synergistic interaction of gemcitabine and cytosine arabinoside with the ribonucleotide reductase inhibitor triapine is schedule dependent. Biochem Pharmacol 73:1548–1557 doi:10.1016/j.bcp.2007.01.025 CrossRefPubMedGoogle Scholar
  8. 8.
    Chen CH, King I, Belcourt M et al (2002) Triapine, a ribonucleotide reductase inhibitor, enhances incorporation of gemcitabine into DNA and cytoxicity to KB cells. Proc AACR-EORTC conference 38:S26 (abstract 71)Google Scholar
  9. 9.
    Yen Y, Margolin K, Doroshow J et al (2004) A phase I trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone in combination with gemcitabine for patients with advanced cancer. Cancer Chemother Pharmacol 54:331–342 doi:10.1007/s00280-004-0821-2 CrossRefPubMedGoogle Scholar
  10. 10.
    Kaufman DC, Chabner BA (2001) Clinical strategies for cancer treatment: the role of drugs. In: Chabner BA, Longo DL (eds) Cancer chemotherapy and biotherapy: principles and practice, 3rd edn. Lippincott, Williams, and Wilkins, Philadelphia, pp 1–16Google Scholar
  11. 11.
    Leslie EM, Deeley RG, Cole SP (2005) Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol Appl Pharmacol 204:216–237 doi:10.1016/j.taap.2004.10.012 CrossRefPubMedGoogle Scholar
  12. 12.
    Rappa G, Lorico A, Liu MC et al (1997) Overexpression of the multidrug resistance genes mdr1, mdr3, and mrp in L1210 leukemia cells resistant to inhibitors of ribonucleotide reductase. Biochem Pharmacol 54:649–655 doi:10.1016/S0006-2952(97)00210-4 CrossRefPubMedGoogle Scholar
  13. 13.
    Kerb R, Hoffmeyer S, Brinkmann U (2001) ABC drug transporters: hereditary polymorphisms and pharmacological impact in MDR1, MRP1 and MRP2. Pharmacogenomics 2:51–64 doi:10.1517/14622416.2.1.51 CrossRefPubMedGoogle Scholar
  14. 14.
    Attia S, Kolesar J, Mahoney MR et al (2008) A phase 2 consortium (P2C) trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) for advanced adenocarcinoma of the pancreas. Invest New Drugs 26:369–379 doi:10.1007/s10637-008-9123-6 CrossRefPubMedGoogle Scholar
  15. 15.
    Marzolini C, Paus E, Buclin T et al (2004) Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther 75:13–33 doi:10.1016/j.clpt.2003.09.012 CrossRefPubMedGoogle Scholar
  16. 16.
    Kim RB, Leake BF, Choo EF et al (2001) Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther 70:189–199 doi:10.1067/mcp.2001.117412 CrossRefPubMedGoogle Scholar
  17. 17.
    Pan JH, Han JX, Wu JM et al (2009) MDR1 single nucleotide polymorphism G2677T/A and haplotype are correlated with response to docetaxel-cisplatin chemotherapy in patients with non-small-cell lung cancer. Respiration. doi:10.1159/000158454
  18. 18.
    Rudin CM, Liu W, Desai A et al (2008) Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity. J Clin Oncol 26:1119–1127 doi:10.1200/JCO.2007.13.1128 CrossRefPubMedGoogle Scholar
  19. 19.
    Ma B, Goh BC, Tan EH et al (2008) A multicenter phase II trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) and gemcitabine in advanced non-small-cell lung cancer with pharmacokinetic evaluation using peripheral blood mononuclear cells. Invest New Drugs 26:169–173 doi:10.1007/s10637-007-9085-0 CrossRefPubMedGoogle Scholar
  20. 20.
    Gautam A, Bepler G (2006) Suppression of lung tumor formation by the regulatory subunit of ribonucleotide reductase. Cancer Res 66:6497–6502 doi:10.1158/0008-5472.CAN-05-4462 CrossRefPubMedGoogle Scholar
  21. 21.
    Gautam A, Li ZR, Bepler G (2003) RRM1-induced metastasis suppression through PTEN-regulated pathways. Oncogene 22:2135–2142 doi:10.1038/sj.onc.1206232 CrossRefPubMedGoogle Scholar
  22. 22.
    Zheng Z, Chen T, Li X et al (2007) DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med 356:800–808 doi:10.1056/NEJMoa065411 CrossRefPubMedGoogle Scholar
  23. 23.
    Davidson JD, Ma L, Flagella M et al (2004) An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines. Cancer Res 64:3761–3766 doi:10.1158/0008-5472.CAN-03-3363 CrossRefPubMedGoogle Scholar
  24. 24.
    Bepler G, Kusmartseva I, Sharma S et al (2006) RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer. J Clin Oncol 24:4731–4737 doi:10.1200/JCO.2006.06.1101 CrossRefPubMedGoogle Scholar
  25. 25.
    Bepler G, Sharma S, Cantor A et al (2004) RRM1 and PTEN as prognostic parameters for overall and disease-free survival in patients with non-small-cell lung cancer. J Clin Oncol 22:1878–1885 doi:10.1200/JCO.2004.12.002 CrossRefPubMedGoogle Scholar
  26. 26.
    Wong SJ, Myette MS, Wereley JP et al (1999) Increased sensitivity of hydroxyurea-resistant leukemic cells to gemcitabine. Clin Cancer Res 5:439–443PubMedGoogle Scholar
  27. 27.
    Duxbury MS, Ito H, Zinner MJ et al (2004) RNA interference targeting the M2 subunit of ribonucleotide reductase enhances pancreatic adenocarcinoma chemosensitivity to gemcitabine. Oncogene 23:1539–1548 doi:10.1038/sj.onc.1207272 CrossRefPubMedGoogle Scholar
  28. 28.
    Souglakos J, Boukovinas I, Taron M et al (2008) Ribonucleotide reductase subunits M1 and M2 mRNA expression levels and clinical outcome of lung adenocarcinoma patients treated with docetaxel/gemcitabine. Br J Cancer 98:1710–1715 doi:10.1038/sj.bjc.6604344 CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  • Anne M. Traynor
    • 1
  • Ju-Whei Lee
    • 2
  • Gerald K. Bayer
    • 3
  • John M. Tate
    • 4
  • Sachdev P. Thomas
    • 5
  • Miroslaw Mazurczak
    • 6
  • David L. Graham
    • 7
  • Jill M. Kolesar
    • 1
  • Joan H. Schiller
    • 8
  1. 1.University of Wisconsin Paul P. Carbone Comprehensive Cancer CenterUniversity of Wisconsin School of Medicine and Public HealthMadisonUSA
  2. 2.Eastern Cooperative Oncology Group and the Department of Biostatistics and Computational BiologyDana-Farber Cancer InstituteBostonUSA
  3. 3.Green Bay Oncology, Saint Vincent HospitalGreen BayUSA
  4. 4.Roger Maris Cancer Center, Merit Care Hospital CCOPFargoUSA
  5. 5.Illinois Cancer CarePeoriaUSA
  6. 6.Sanford Clinic OncologySanford HospitalSioux FallsUSA
  7. 7.Carle Cancer AssociationUrbanaUSA
  8. 8.Division of Hematology and Oncology, Department of Internal MedicineUniversity of Texas at Southwestern Medical CenterDallasUSA

Personalised recommendations